<DOC>
	<DOCNO>NCT00731224</DOCNO>
	<brief_summary>This study evaluate compliance , tolerability , safety , efficacy caregiver burden rivastigmine patch 10 cm² treatment people Alzheimer 's disease ( MMSE 10-26 ) initiate therapy first time cholinesterase inhibitor , patient unresponsive previous cholinesterase inhibitor treatment community setting .</brief_summary>
	<brief_title>Compliance Tolerability Rivastigmine Transdermal Patch 10 cm² Patients With Probable Alzheimer 's Disease .</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Probable Alzheimer 's disease accord NINCDSADRDA ( National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ) DSMIV ( Diagnostic Statistical Manual Mental Disorders ) criterion ; MMSE score ≥10 ≤ 26 ; Bradycardia ( beat per minute le 50 ) Body weight less 40 kg ; Hypersensitivity cholinesterase inhibitor . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's disease , rivastigmine , patch</keyword>
</DOC>